Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 21, 2016 10:30:34 GMT -5
What's interpretation on this bit? "MannKind will also transfer manufacturing technology to the licensee" Is this a transfer of TS IP? That doesn't sit well for nothing upfront + possible $100m down the road + possible ~10% sales down the road Can it be viewed as a spinoff of TS? Its exactly what it is - Manufacturing technology so Mannkind doesnt have to run production facility. They didnt say Technosphere IP
|
|
|
Post by mindovermatter on Jan 21, 2016 10:30:41 GMT -5
good points. now that this is out of the way, the next fire to put out is how Mannkind can raise much needed cash unless Receptor Life is part of a plan to take MNKD private. Why not read the MannKind 2016 Blueprint Summary (posted above)? It's covered there: "Generate immediate cash and increase volume by rapid expansion into selected international jurisdictions."
Can I hear an "Israel - amen, brother!" Saudi Arabia? Others include any country that basically rubber stamps FDA-approved drugs.
Seriously, are shareholders, who have been complaining for years about lack of transparency, ignoring Matt Pfeffer (out of habit) now that MannKind's new CEO is providing guidance?
Yes again good points and something we have been waiting for, that is moving Afrezza out of USA and negotiate a revenue stream from a foreign country or two.
|
|
|
Post by mindovermatter on Jan 21, 2016 10:31:43 GMT -5
good points. now that this is out of the way, the next fire to put out is how Mannkind can raise much needed cash unless Receptor Life is part of a plan to take MNKD private. Yes, because as we've seen in the past every deal MNKD does has a secret plan to buy them out for billions. It must be getting so confusing with all these companies behind the scenes now fighting over their rights to give us shareholders billions. Stop it! Can we please have a wild buy out speculation free zone here at Proboards. There is ZERO reason to believe there is anything beyond what was announced. Whoa! Take it easy man! Taking Mannkind private doesn't mean that shareholders are going to hit the jackpot. You are reading things into my comments that are not there! My comment wasn't hinting to mean that there is going to be some huge buyout. You obviously are suffering from PSTD from hypers. I don't think I am hyping here at all.
|
|
|
Post by mnholdem on Jan 21, 2016 10:31:58 GMT -5
Amazing! I also thought of Chris Veihbacher when I read the announcement... regardless, let's hope (I'm not afraid to use that word) that whoever is behind our new partner is a visionary with lots of financial muscle.
|
|
|
Post by nuklerfizzacist on Jan 21, 2016 10:32:02 GMT -5
For the sake of the prior baseball analogies that were posted here; no it's not the homerun many here are yearning for but I'll take this sweet little single to start the rally.... P.S. Stevil...depends on what the ~10% is based off of ...right? :-) as an optimist I'm thinking it must be 5-10 percent of more than you may be thinking. ..just my guess. ;-) Let's throw numbers out so people can see what we're talking about. I don't know how generous you want to be regarding future sales, but at around 10-15% sales royalties, (single digit to low double-digit) even at $1billion/year, we only get $100-150 millon/year. That's roughly our current burn rate. So we're not going to be able to develop the company further with R&D, not be able to hire new employees, not be able to pay a new CEO, although if Matt pulls this off we probably don't need one. But hopefully you get my point. This is merely a tourniquet right now to keep us from hemorrhaging out. This will not save the company by itself. We need more, and likely much better if we want this company to survive. From the comments, it sounds like Matt is still counting on Afrezza to become what we all hoped it would and that's what we're banking on. Keep the ship afloat long enough until Afrezza catches traction. I don't see how this deal does that for us in the short term, but I guess we need to take what we can get right now just to try. I do get your point....and perhaps like you, i do try to remain optimistic regarding the great product that mnkd has produced and the future of that great product...it is way too easy to present a negative outlook at this juncture and I'm just trying to balance things out. .not a pumper, not a basher, not a trader, I'm an investor and until i think this is a bad investment I'll be here. .when i think it's bad i will not sit here and carp.
|
|
|
Post by dpca10 on Jan 21, 2016 10:32:02 GMT -5
What I want to know is how much of our current cash burn will this license alleviate, if any? The important thing is get all unnecessary expenses off our books. This seems to keep our future projects and not divert unnessary resources. One of these might turn out to be a Ferrari but right now they are just a bucket of parts. The alternative would be to ditch the projects entirely.
|
|
|
Post by factspls88 on Jan 21, 2016 10:32:42 GMT -5
CEO Pfeffer is sticking with the plan. This announcement is listed under the bullet point that speaks to Technosphere licensing and partnership agreements to be fast-tracked, building a portfolio for future growth, "beginning with the licensing agreement about to be announced."
Good to see that their first bullet has to do with lowering the price. It'll be interesting to see hear when they plan to implement it. I'm not sold on the social media angle UNLESS they hire a real expert to execute it for them. I think running ads targeted at diabetics in Facebook could be compelling if done right given the high involvement diabetics have with their disease. Twitter has been great for us investors (perhaps too great) but I'm not so sure there are enough potential users to have a significant impact.
|
|
|
Post by od on Jan 21, 2016 10:33:10 GMT -5
Website was created 11 days ago.
Domain Name: RECEPTORLIFE.COM Registrar: ENOM, INC. Sponsoring Registrar IANA ID: 48 Whois Server: whois.enom.com Referral URL: www.enom.com Name Server: DNS1.REGISTRAR-SERVERS.COM Name Server: DNS2.REGISTRAR-SERVERS.COM Name Server: DNS3.REGISTRAR-SERVERS.COM Name Server: DNS4.REGISTRAR-SERVERS.COM Name Server: DNS5.REGISTRAR-SERVERS.COM Status: clientTransferProhibited www.icann.org/epp#clientTransferProhibited Updated Date: 10-jan-2016 Creation Date: 10-jan-2016 Expiration Date: 10-jan-2017
Goes to show that this announcement is a complete joke. Same managment team, same results. nemzter, please explain. The newly registered URL is consistent with "...a newly formed entity, Receptor Life Sciences, Inc...". I am not overly excited about the announcement, but not sure I understand your thinking.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 21, 2016 10:34:56 GMT -5
Amazing! I also thought of Chris Veihbacher when I read the announcement... regardless, let's hope (I'm not afraid to use that word) that whoever is behind our new partner is a visionary with lots of financial muscle. if so , it wouldnt be made public until the year end when Chris Veihbacher and DeSisto both are no more held back their Competitive clause and Receptor life hires them lol..
|
|
|
Post by mnholdem on Jan 21, 2016 10:35:33 GMT -5
What's interpretation on this bit? "MannKind will also transfer manufacturing technology to the licensee" Is this a transfer of TS IP? That doesn't sit well for nothing upfront + possible $100m down the road + possible ~10% sales down the road Can it be viewed as a spinoff of TS? Its exactly what it is - Manufacturing technology so Mannkind doesnt have to run production facility. They didnt say Technosphere IP The key here is "licensing". MannKind is getting back to what it is - a drug development company, rather than a manufacturer.
|
|
ssaq
Newbie
Posts: 13
|
Post by ssaq on Jan 21, 2016 10:36:33 GMT -5
good points. now that this is out of the way, the next fire to put out is how Mannkind can raise much needed cash unless Receptor Life is part of a plan to take MNKD private. Why not read the MannKind 2016 Blueprint Summary (posted above)? It's covered there: "Generate immediate cash and increase volume by rapid expansion into selected international jurisdictions."
Can I hear an "Israel - amen, brother!" Saudi Arabia? Others include any country that basically rubber stamps FDA-approved drugs.
Seriously, are shareholders, who have been complaining for years about lack of transparency, ignoring Matt Pfeffer (out of habit) now that MannKind's new CEO is providing guidance?
Matt & Co. has said a lot over the last year. Yes, a deal finally signed but there is no immediate cash, or clarity as to when (or even if) cash will actually come from this deal. I think shareholders would like to know the truth (to the extent that is not damaging to prospects). He gave us hopes and dreams; needs to follow up regularly with some facts to show he's executing the plan/vision..
|
|
|
Post by dpca10 on Jan 21, 2016 10:37:18 GMT -5
Also "pain, neurologic diseases and inflammatory disorders." were mentioned. I don't see pulmonary in there. Pulm htn could be considered inflammatory in some cases but not really an appropriate description. I wonder if this is just a spin off of a few products and not the most promising candidate for pulmonary hypertension.
|
|
|
Post by biffn on Jan 21, 2016 10:42:09 GMT -5
Website was created 11 days ago.
Domain Name: RECEPTORLIFE.COM Registrar: ENOM, INC. Sponsoring Registrar IANA ID: 48 Whois Server: whois.enom.com Referral URL: www.enom.com Updated Date: 10-jan-2016 Creation Date: 10-jan-2016 Expiration Date: 10-jan-2017
ENOM is located in Kirkland, WA, about 2 miles and essentially down the street from Microsoft HQ in Redmond. May not be a coincidence.
|
|
|
Post by factspls88 on Jan 21, 2016 10:47:25 GMT -5
Its exactly what it is - Manufacturing technology so Mannkind doesnt have to run production facility. They didnt say Technosphere IP The key here is "licensing". MannKind is getting back to what it is - a drug development company, rather than a manufacturer. As long as they intend to market Afrezza, I'm afraid they are still in the manufacturing/marketing business, but it is good that they have chosen this route for the new drug candidates.
|
|
|
Post by mnholdem on Jan 21, 2016 10:48:04 GMT -5
Why not read the MannKind 2016 Blueprint Summary (posted above)? It's covered there: "Generate immediate cash and increase volume by rapid expansion into selected international jurisdictions."
Can I hear an "Israel - amen, brother!" Saudi Arabia? Others include any country that basically rubber stamps FDA-approved drugs.
Seriously, are shareholders, who have been complaining for years about lack of transparency, ignoring Matt Pfeffer (out of habit) now that MannKind's new CEO is providing guidance?
Matt & Co. has said a lot over the last year. Yes, a deal finally signed but there is no immediate cash, or clarity as to when (or even if) cash will actually come from this deal. I think shareholders would like to know the truth (to the extent that is not damaging to prospects). He gave us hopes and dreams; needs to follow up regularly with some facts to show he's executing the plan/vision.. Agreed. I think Matt has stated that he plans to provide shareholder updates regularly. Bring it on!
|
|